2-cyclobutyl-1H-imidazo[4,5-c]pyridine | 119628-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-cyclobutyl-1H-imidazo[4,5-c]pyridine
• 英文别名: 2-cyclobutyl-3H-imidazo[4,5-c]pyridine
• CAS: 119628-86-3
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: WVPGUNFEMDBITD-UHFFFAOYSA-N

物化性质

• 沸点：
  435.2±18.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-cyclobutyl-1H-imidazo[4,5-c]pyridine 在 间氯过氧苯甲酸 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 氯仿 为溶剂， 反应 5.0h， 以20%的产率得到4-chloro-2-cyclobutyl-1H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  DIBENZOOXEPIN DERIVATIVE

  摘要：

  公开号：

  EP2740730B1
• 作为产物：
  描述：

  3,4-二氨基吡啶 、 环丁基甲酸 在 polyphosphoric acid 作用下， 反应 3.0h， 以73%的产率得到2-cyclobutyl-1H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  DIBENZOOXEPIN DERIVATIVE

  摘要：

  公开号：

  EP2740730B1

文献信息

• Dibenzooxepin derivative
  申请人：Yamamoto Keisuke

  公开号：US08969345B2

  公开（公告）日：2015-03-03

  A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPARγ agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.

  提供了一种二苯并氧吩衍生物，其通式表示为（I），其中Y为氢原子等，RA为氢原子等，X为式（b3），其中RB为氢原子等，A为式（a18），其中R1为氢原子等，RC和RD相同或不同，且每个为氢原子等，该物质具有PPARγ激动剂活性等，可用作治疗和/或预防2型糖尿病等的治疗剂和/或预防剂等，或其药学上可接受的盐等。
• Discovery of Dual Inducible/Neuronal Nitric Oxide Synthase (iNOS/nNOS) Inhibitor Development Candidate 4-((2-Cyclobutyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1<i>H</i>)-one (KD7332) Part 2: Identification of a Novel, Potent, and Selective Series of Benzimidazole-Quinolinone iNOS/nNOS Dimerization Inhibitors That Are Orally Active in Pain Models
  作者：Joseph E. Payne、Céline Bonnefous、Kent T. Symons、Phan M. Nguyen、Marciano Sablad、Natasha Rozenkrants、Yan Zhang、Li Wang、Nahid Yazdani、Andrew K. Shiau、Stewart A. Noble、Peter Rix、Tadimeti S. Rao、Christian A. Hassig、Nicholas D. Smith

  DOI：10.1021/jm100828n

  日期：2010.11.11

  Three isoforms of nitric oxide synthase (NOS), dimeric enzymes that catalyze the formation of nitric oxide (NO) from arginine, have been identified. Inappropriate or excessive NO produced by iNOS and/or nNOS is associated with inflammatory and neuropathic pain. Previously, we described the identification of a series of amide-quinolinone iNOS dimerization inhibitors that although potent, suffered from high clearance and limited exposure in vivo. By conformationally restricting the amide of this progenitor series, we describe the identification of a novel series of benzimidazole-quinolinone dual iNOS/nNOS inhibitors with low clearance and sustained exposure in vivo. Compounds were triaged utilizing an LPS challenge assay coupled with mouse and rhesus pharmacokinetics and led to the identification of 4,7-imidazopyrazine 42 as the lead compound. 42 (KD7332) (J. Med. Chem. 2009, 52, 3047-3062) was confirmed as an iNOS dimerization inhibitor and was efficacious in the mouse formalin model of nociception and Chung model of neuropathic pain, without showing tolerance after repeat dosing. Further 42 did not affect motor coordination up to doses or 1000 mg/kg, demonstrating a wide therapeutic margin.
• OEZDEN, S., ANKARA UENIV. ESZACILIK FAK. MECMUASI, 1981, 11, N 1, 80-102
  作者：OEZDEN, S.

  DOI：——

  日期：——
• US8969345B2
  申请人：——

  公开号：US8969345B2

  公开（公告）日：2015-03-03
• DIBENZOOXEPIN DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2740730B1

  公开（公告）日：2016-11-16